Lipid Binding Protein Complexes for Ocular Lipid Removal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for eye diseases associated with lipid accumulation, such as fish-eye disease, lack specific therapies, relying on symptom relief with no effective methods to correct LCAT deficiency, leading to progressive vision impairment and potential blindness.
Innovation Solution
The use of lipid binding protein-based complexes, like CER-001, to solubilize and eliminate ocular lipid deposits, either systemically or locally, as a drug carrier for ophthalmic drugs to treat various eye diseases, including those related to LCAT deficiency, through specific dosing regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for eye diseases associated with lipid accumulation are used, then symptom relief is provided, but no effective correction of LCAT deficiency occurs leading to progressive vision impairment
Solution Approach 1:
The patent uses lipoprotein complexes as intermediary carriers to deliver ophthalmic drugs to the eye. These complexes mimic natural lipoproteins and can solubilize lipid deposits while transporting therapeutic agents, thereby enabling effective treatment of LCAT deficiency-related eye diseases where no specific therapy previously existed.
2Reliability
If lipid binding protein-based complexes are used to solubilize and eliminate ocular lipid deposits, then the severity and progression of eye diseases is reduced, but the complexity of the treatment mechanism increases
Solution Approach 1:
The lipoprotein complexes perform multiple functions simultaneously: they solubilize lipid deposits, serve as drug carriers, and deliver therapeutic agents to the eye. This multi-functionality reduces the need for separate treatment mechanisms, thereby managing disease effectiveness while controlling overall treatment complexity.
3Productivity
If lipid binding protein-based complexes are used as drug carriers to deliver ophthalmic drugs directly to the eye, then drug delivery efficiency is improved, but the complexity of the delivery system increases
Solution Approach 1:
The lipoprotein complexes utilize their natural affinity for lipid environments to automatically target and deliver drugs to ocular tissues. The complexes self-assemble and self-target based on their lipid-binding properties, reducing the need for complex external targeting mechanisms while maintaining high delivery efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces the severity and slows the progression of eye diseases by effectively managing ocular lipid deposits and delivering ophthalmic drugs directly to the eye, offering a potential treatment for conditions like fish-eye disease and other lipid-related disorders.
Implementation Method 1
lipid binding protein-based complexes, like CER-001, to solubilize and eliminate ocular lipid deposits
Implementation Method 2
as a drug carrier for ophthalmic drugs to treat various eye diseases
Data Source
AI summary
Methods for treating eye diseases, for example eye diseases associated with lipid accumulation, with lipid binding protein-based complexes such as CER-001; lipid binding protein-based complexes, compositions comprising a lipid binding protein-based complex as a carrier for one or more ophthalmic drugs, and uses thereof.